Squire Patton Boggs has advised the shareholders of Datapharm, a leading provider of regulatory-driven medicines information and software solutions to the pharmaceutical industry, on the investment in the company by CGE Partners, the European mid-market investment fund.
The Squire Patton Boggs team advising Datapharm on the investment was led by Corporate partner Mark Yeo in London.
The Squire Patton Boggs team included Corporate senior associates Joe Abbott, Roya Soudbakhsh and Matt Lappin, Corporate associates Isabelle Sadler, Simon Ayling and James Pascoe, Corporate trainee Milena Bohn, Tax partner Patrick Ford, Tax associate Alex Paterson, Labour & Employment associate Will Saunders, and Intellectual Property & Technology associate Charlotte Lister.
Datapharm is a medicines information company that provides technology-enabled solutions to the global life sciences and wider healthcare sectors. Its regulatory, compliance and commercial software solutions facilitate the accessibility and usability of medicines information to healthcare professionals and patients. The business supports pharmaceutical companies in maintaining regulatory compliance and its software solutions are trusted by over 300 of the world’s top global life sciences companies. Datapharm’s core platform, the electronic medicines compendium, is the UK’s leading source of trusted medicines information used by pharmaceutical companies, healthcare professionals, and patients.
CGE invests in businesses using technology to facilitate the transition to a more digital, renewable, secure and compliant future, providing capital and expertise to accelerate expansion in global markets. CGE is partnering with Datapharm’s management team to accelerate new product development, international expansion, and strategic acquisitions.